PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wjgLink to Publisher's site
 
World J Gastroenterol. 2010 May 7; 16(17): 2129–2133.
Published online 2010 May 7. doi:  10.3748/wjg.v16.i17.2129
PMCID: PMC2864838

Presence of hepcidin-25 in biological fluids: Bile, ascitic and pleural fluids

Abstract

AIM: To examine body fluids such as ascitic fluid (AF), saliva, bile and pleural effusions for the presence of hepcidin using a novel radioimmunoassay (RIA).

METHODS: Serum samples were collected from 25 healthy volunteers (mean age: 36 ± 11.9 years, 11 males, 14 females). In addition bile was obtained from 12 patients undergoing endoscopic retrograde cholangiopancreatography (mean age: 66.9 ± 16.7 years, M:F = 5:7). Saliva was collected from 17 healthy volunteers (mean age: 35 ± 9.9 years, M:F = 8:9). Pleural and AF were collected from 11 and 16 patients [(mean age: 72 ± 20.5 years, M:F = 7:4) and (mean age: 67.32 ± 15.2 years, M:F = 12:4)], respectively. All biological fluid samples (serum, exudative and transudative fluids) were tested for the presence of hepcidin-25 molecule using RIA.

RESULTS: Hepcidin-25 was detected in all biological fluids tested. The mean ± SD hepcidin-25 in serum was 15.68 ± 15.7 ng/mL, bile 7.37 ± 7.4 ng/mL, saliva 3.4 ± 2.8 ng/mL, exudative fluid 65.64 ± 96.82 ng/mL and transudative fluid 14.1 ± 17.8 ng/mL.

CONCLUSION: We provide clear evidence that hepcidin-25 is present in bile, saliva, pleural and ascitic fluids. Hepcidin is likely to play a role here in innate immunity.

Keywords: Hepcidin, Hepcidin assay, Hepcidin in biological fluids, Hepcidin in ascitic fluid, Bile, Exudates, Antimicrobial peptides

INTRODUCTION

Hepcidin-25 is a cysteine-rich circulating bioactive peptide that is predominantly secreted from the liver and excreted in the urine[1]. It is synthesized as preprohepcidin and undergoes posttranslational processing before release into circulation in an active form[2]. It is a central iron regulator with in-vitro evidence of antimicrobial properties. Hepcidin exerts its regulatory effect by preventing the efflux of intracellular iron by binding to ferroportin channels[3]. These ferroportin channels are present on the basal surface of the intestinal enterocytes as well as hepatocytes, macrophages and placental cells and are predominantly involved in the export of iron from these cells[4]. Despite a considerable body of literature on this novel peptide, research has been impeded by the lack of a reliable assay. Initially a semi quantitative assay (immunodot) was described but more recently quantitative assays have been developed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS)[5] and liquid chromatography tandem MS (LC-MS/MS)[6,7].

We developed and validated a radioimmunoassay (RIA) for hepcidin-25 and measured serum levels of hepcidin-25 in various patient groups[8]. In this manuscript, we describe the use of RIA to demonstrate and measure hepcidin-25 in various biological fluids.

MATERIALS AND METHODS

This was a prospective study performed with approval of our Regional Ethics Committee and written consent was obtained from all patients and healthy volunteers in accordance with the Declaration of Helsinki. Patients and healthy volunteers were recruited from a single hospital with mixed ethnicity mainly comprising Caucasians and South Asians living in West London.

Healthy controls

The serum study comprised of 25 healthy controls (HC); 14 were females, mean age was 36 ± 11.9 years (age range: 21-62 years), were hospital colleagues recruited to measure serum hepcidin-25, ferritin and serum prohepcidin. HC with systemic illness (acute or chronic) or any history of regular use of medication including supplemental vitamins were excluded. A fasting venous blood sample was obtained between 08:30-09:00 h. Serum was separated and stored at -20°C for analysis.

Bile

Bile was collected from 12 patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) for proven or suspected choledocholithiasis, mean age 66.9 ± 16.7 years, M:F = 5:7 (age range: 40-88 years). All patients had ultrasonography (USG) of the abdomen to identify choledocholithiasis, or cholelithiasis. Ten out of 12 patients recruited had cholelithiasis confirmed on USG. Two patients had a dilated common bile duct (CBD) without choledocholithiasis. During ERCP, CBD was cannulated and 2 mL of bile was aspirated before injecting contrast medium for CBD visualisation. Stone extraction or biliary sludge removal including sphincterotomy was done after bile collection to avoid contamination. Bile obtained was stored at -20°C.

Saliva

Saliva was obtained from a separate cohort of 17 healthy volunteers, mean age of 35 ± 9.9 years (age range: 23-60 years), M:F = 8:9. A history of systemic illness or dental or pharyngeal pathology was excluded. Participants were not allowed to eat or drink 30 min before the collection of saliva. Ten minutes before collection, participants had to rinse their mouth with plain water. They had to chew on a cotton swab and return the same with saliva in sterile tube (Salivette, Sarstedt, UK) and stored at -20°C.

Pleural fluid

Eleven patients, mean age 72 ± 20.5 years (age range: 26-95 years), M:F = 7:4 were recruited for pleural fluid (PF) analysis. PF was collected by diagnostic thoracocentesis under sterile conditions and stored in a sterile container at -20°C. PF was analysed and divided into a transudate and exudate by comparing the total protein concentrations in fluid to that in blood as per Light’s Criteria[9]. Three patients had transudative fluid (PF-T) (M:F = 2:1). The underlying cause for fluid accumulation in this group was congestive heart failure secondary to ischemic heart disease. Eight patients had exudative fluid (PF-E) (M:F = 5:3). The underlying cause for fluid accumulation in this cohort was parapneumonic (5 cases) and neoplastic [3 cases (1 breast and 2 lung malignancies)].

Ascitic fluid

Ascitic fluid (AF) was collected from 16 patients, mean age 67.32 ± 15.2 years (age range: 42-85 years), M:F = 12:4 under sterile conditions by diagnostic paracentesis as further differentiated by serum/ascites albumin gradient (SAAG)[10]. Twelve patients were identified as having transudative ascites (AF-T) (M:F = 8:4). Alcohol induced liver cirrhosis was the aetiology and comprised majority with 10 patients. The remaining 2 patients had chronic hepatitis B and chronic hepatitis C as etiology. The exudative ascites cohort comprised 2 patients (AF-E) (M:F = 2:0), with aetiology being congestive heart failure secondary to ischemic heart disease and idiopathic.

One patient had transudative AF with spontaneous bacterial peritonitis (SBP) (M:F = 1:0) analysed for presence of hepcidin-25. The cause of ascites was cirrhosis of the liver secondary to alcohol misuse. The AF white cell count was 350/mm3 (90% polymorphs, 10% lymphocytes) and AF culture had grown Escherichia coli (E. coli).

On the basis of above, 2 cohorts were obtained, those with Transudative Fluid and those with Exudative Fluid, comprising both pleural and AFs in each respective category. One patient with SBP-ascites was excluded from the transudative fluid group. Thus, there were 10 patients in the total exudative fluid cohort (M:F = 7:3) and 15 patients in the total transudative fluid cohort (M:F = 10:5).

Assay

Hepcidin-25 was measured using a novel competitive RIA. This was produced in our laboratory and has been described in our previous manuscript (Busbridge et al[8]).

The specificity of the antibody was also confirmed by Western blotting analysis of the precipitated proteins, where a single band of < 6 kDa was detected. Western blotting analysis was carried out by using 10 mL normal human plasma, which was first centrifuged and filtered through a 0.22 mm filter (Millipore, MA). After addition of 10-mL dithiothreitol, plasma was again filtered through a 30 kDa filter (Millipore) and the filtrate precipitated using 25% TCA. The precipitated proteins were resuspended in loading buffer and subjected to SDS electrophoresis on a 4%-16% NuPAGE Novex Bis/Tris gel (Invitrogen, UK). Western blotting was performed using an XCell II blot module (Invitrogen) and a 0.1 mm pore size nitrocellulose membrane (Sigma Aldrich). Non-specific sites were blocked with 5% BSA in PBS and the membrane probed with purified rabbit anti-hepcidin antibody (1 in 2000 dilution in blocking buffer), followed by incubation with a secondary anti-rabbit antibody conjugated with horseradish peroxidase (Sigma Aldrich). Specific signals were detected with 3,3’, 5,5’ tetramethylbenzidine liquid substrate (Sigma Aldrich) (Figure (Figure11).

Figure 1
Western blotting analysis of serum proteins using rabbit anti-hepcidin antibody demonstrating the presence of a protein band at < 6 kDa.

Serum prohepcidin was measured by enzyme linked immunosorbent assay (ELISA) (DRG Diagnostics, UK) as per manufacturer’s guidelines. Ferritin, iron and C-reactive protein were measured using Abbott Architect ic8000 system (Abbott Diagnostics, Ireland).

Statistical analysis

Values are expressed as mean ± SD as indicated. Quantitative variables were compared using unpaired t-test; Pearson’s rank correlation was used for calculating correlation between the hepcidin-25 and other variables. A value of P < 0.05 was considered significant. All statistical analyses were carried out using the statistical package GraphPad Prism version 5.0 for Windows, (GraphPad Software, San Diego California USA, http://www.graphpad.com).

RESULTS

HC

Serum hepcidin in HC was 15.30 ± 15.71 ng/mL with a range of 1.1-55.0 ng/mL. The mean prohepcidin was 236.88 ± 83.68 ng/mL and the mean ferritin was 110.00 ± 128.08 μg/L. There was no correlation between serum prohepcidin and ferritin in healthy volunteers. However, serum hepcidin showed a weak correlation with ferritin (r = 0.174, P < 0.05).

Bile and saliva cohort

Hepcidin-25 was detected in all bile samples (n = 12) and was measured at a mean of 7.37 ± 7.39 ng/mL with a range of < 1.0-23 ng/mL. Hepcidin-25 was detected in saliva with a mean of 3.39 ± 2.83 ng/mL, range of < 0.9-11.8 ng/mL.

Exudative and transudative fluid

Hepcidin-25 level was 65.64 ± 96.82 ng/mL in exudative fluid. The mean total protein level in the fluid was 43.69 g/L. The hepcidin-25 level was 14.10 ± 17.88 ng/mL in transudative fluid. Hepcidin-25 concentration in exudative fluid was higher than in transudative but did not reach statistical significance (P = 0.05, student t-test). This could be due to the small number of patients involved in the study. We demonstrated hepcidin-25 in all bodily fluids analysed using RIA. To our knowledge this is the first report confirming the presence of hepcidin-25 in these bodily fluids (Figure (Figure22).

Figure 2
Scatter-dot plot of hepcidin data from healthy control sera (HC) and various body fluids, bile, saliva and pleural fluid both exudates and transudate in nature. Data is presented with geometric mean and 95% CI levels.

DISCUSSION

Hepcidin, as an antimicrobial peptide, was first described as a liver expressed antimicrobial peptide 1[11].

Hepcidin is a novel peptide due to its dual role as an ‘iron-hormone’ and ‘antimicrobial peptide’. However, previous research studies have been hampered due to lack of a reliable quantitative assay for hepcidin-25. Several factors have been cited for this difficulty including presence of non-biologically active iso-forms of hepcidin-20, hepcidin-22, and the fact that hepcidin-25 is conserved over evolution thus making an immunological response in host species difficult to determine[12]. Several semi quantitative and quantitative assays have recently been developed for hepcidin-25 measurement. The quantitative assays include ELISA[13] and MS. MS methods includes TOF-MS, LC-MS, matrix-assisted laser desorption ionization MS, and SELDI-MS[14,15]. Although very successful, the availability of the MS assay is limited to specialist laboratories as they require strict internal standards and specialised equipment. Two quantitative assays have been described using ELISA techniques. Ganz et al[13] have described a competitive quantitative ELISA assay using functional synthetic peptide hepcidin-25 while the method described by Koliaraki et al[16] detects hepcidin-25 using a recombinant functional hepcidin-25 peptide. Thus, although a number of methods are available to measure hepcidin-25, there does not appear to be a standardisation amongst various methods. The results of the first international round robin for the quantification of urinary and plasma hepcidin assays were published in an attempt to help standardisation issues[17].

Until recently, hepcidin-25 was shown to be present in urine and serum. However, its expression by various organs such as salivary glands, tonsils, trachea, lung and prostate have also been reported[18]. The exact nature and function of hepcidin expression in these organs remains unclear.

Hepcidin in saliva

This study confirms the presence of hepcidin-25 in saliva. Its exact role in saliva is still uncertain but could contribute to the broad spectrum defence of the oral cavity along with peptides such as cathelicidins[19].

Hepcidin in bile

The presence of hepcidin-25 in bile may be a mechanism of hepcidin-25 excretion apart from urine. It may act along with α-defensins against gut microflora[20]. Further studies are needed to fully understand its role in bile.

Hepcidin in PF and AF

We were able to demonstrate the presence of hepcidin in pleural and AF where its iron regulator function is hard to explain. Hepcidin present in these fluids has unknown biological activity. Hepcidin-25 is a cationic peptide with 4 disulfide bridges[21]. The connection between hepcidin and infection/inflammation became clearer after the initial discovery in 2000. Shike et al[22], in 2002 showed that in white bass liver, infection with the fish pathogen Streptococcus iniae increased hepcidin mRNA expression 4500-fold. In another study by Nicolas et al[23] in 2002 injections of turpentine, a standard inflammatory stimulus, into mice induced hepcidin mRNA 4-fold and led to a 2-fold decrease in serum iron.

Hepcidin maintains a role in host defence by acting as a bridge between immunity and iron metabolism, as indicated by markedly induced hepcidin by infection and inflammation[24-26]. Park et al[1] have shown that hepcidin has antimicrobial activity against E. coli, Staphylococcus aureus, Staphylococcus epidermidis and group B Streptococcus. Hepcidin also exhibits antifungal activity against Candida albicans, Aspergillus niger and Aspergillus fumigatus.

Our study on the presence of hepcidin in bile, saliva and various other biological fluids provides further confirmatory evidence that hepcidin has evolved from being an antimicrobial peptide. Hepcidin may form part of human innate immunity and complement other antimicrobial peptides to provide a wide spectrum of mucosal immunity against pathogens.

COMMENTS

Background

Until recently iron metabolism had been extensively studied but poorly understood. With the discovery of hepcidin as an iron regulator in the body, there has been a significant growth in the knowledge related to iron metabolism. Crucial research has been done to explore the role of hepcidin in iron deficiency anaemia, anaemia of chronic disease and iron excess disorders.

Research frontiers

Hepcidin is a 25 amino-acid peptide predominantly formed in the liver and is a key component in iron homeostasis. Its major role is to prevent iron export by binding to iron export channels, ferroportin, leading to internalisation and lysosomal degradation of the hepcidin-ferroportin complex. Interestingly, hepcidin is found throughout evolution and in amphibian species has possible antimicrobial properties while in humans its major action is iron metabolism. Prior research showed hepcidin expression in various human organs like heart, intestine and salivary glands. In this study, the authors demonstrate clear evidence that hepcidin is present in various bodily fluids with higher levels found in exudative fluids and could be a potential mechanism for innate immunity preserved over evolution.

Innovations and breakthroughs

Recent studies have highlighted the importance of hepcidin in iron metabolism, particularly anaemia of chronic disease and iron overload. There have also been reports of its expression in various proinflammatory disorders and various organs, linking it to innate immunity and iron metabolism. This is the first study to report that hepcidin is found in various biological fluids. Furthermore, in-vitro studies have suggested that hepcidin has antimicrobial activity.

Applications

By understanding how hepcidin is expressed and by blocking its expression, there may be a therapeutic potential in patients with anaemia of chronic inflammation. Further application could be that secondary infection of pleural and ascitic fluid complicating underlying diseases may be better understood by studying hepcidin levels in infected and non-infected patients.

Terminology

Hepcidin is a protein involved in iron metabolism. Hepcidin is formed predominantly in the liver and is released in the circulation where its major function is hypoferremia by binding to iron export channel ferroportin. Hepcidin is expressed by various organs and thus it was conceivable that hepcidin would be found in various biological fluids. The exact role of hepcidin in these fluids remains uncertain and more studies are needed.

Peer review

The authors present a nicely conceived and analysed study. It is well written and offers new information about the presence of hepcidin in human biological fluids.

Acknowledgments

We thank Mr. Kamran Qureshi for his valuable help in collecting bile samples. We are indebted to Dr. Amar Sharif for advice and assistance.

Footnotes

Supported by Grant from Ealing Hospital NHS Trust, Imperial College, United Kingdom

Peer reviewers: Alberto Piperno, Professor, Department of Clinical Medicine and Prevention, Clinical Medicine, San Gerardo Hospital, Via Pergolesi 33, 20052, Monza, Italy; Kostas Pantopoulos, Associate Professor, Department of Medicine, McGill University, Lady Davis Institute for Medical Research, 3755 Cote Ste-Catherine Road, Montreal, Quebec, H3T 1E2, Canada; Ioannis E Koutroubakis, MD, PhD, Assistant Professor of Medicine, Department of Gastroenterology, University Hospital Heraklion, PO Box 1352, 71110 Heraklion, Crete, Greece

S- Editor Wang YR L- Editor O’Neill M E- Editor Zheng XM

References

1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810. [PubMed]
2. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis. 2008;40:132–138. [PMC free article] [PubMed]
3. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093. [PubMed]
4. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906–19912. [PubMed]
5. Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine hepcidin assay by mass spectrometry. Blood. 2005;106:3268–3270. [PubMed]
6. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381–1387. [PubMed]
7. Li H, Rose MJ, Tran L, Zhang J, Miranda LP, James CA, Sasu BJ. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods. 2009;59:171–180. [PubMed]
8. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A, Chapman RS. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci. 2009;66:150–157. [PubMed]
9. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–513. [PubMed]
10. Beg M, Husain S, Ahmad N, Akhtar N. Serum/ascites albumin gradient in differential diagnosis of ascites. J Indian Acad Clin Med. 2001;2:51–54.
11. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480:147–150. [PubMed]
12. Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, Papatheodoridis G, Stamoulakatou A, Swinkels DW, Papanikolaou G, et al. A novel immunological assay for hepcidin quantification in human serum. PLoS One. 2009;4:e4581. [PMC free article] [PubMed]
13. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–4297. [PubMed]
14. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One. 2008;3:e2706. [PMC free article] [PubMed]
15. Bozzini C, Campostrini N, Trombini P, Nemeth E, Castagna A, Tenuti I, Corrocher R, Camaschella C, Ganz T, Olivieri O, et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis. 2008;40:347–352. [PubMed]
16. Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, Papatheodoridis G, Stamoulakatou A, Swinkels DW, Papanikolaou G, et al. A novel immunological assay for hepcidin quantification in human serum. PLoS One. 2009;4:e4581. [PMC free article] [PubMed]
17. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94:1748–1752. [PubMed]
18. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93:90–97. [PubMed]
19. Murakami M, Ohtake T, Dorschner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J Dent Res. 2002;81:845–850. [PubMed]
20. Arnold J, Sangwaiya A, Bhatkal B, Geoghegan F, Busbridge M. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol. 2009;21:425–429. [PubMed]
21. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem. 2002;277:37597–37603. [PubMed]
22. Shike H, Lauth X, Westerman ME, Ostland VE, Carlberg JM, Van Olst JC, Shimizu C, Bulet P, Burns JC. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur J Biochem. 2002;269:2232–2237. [PubMed]
23. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA. 2002;99:4596–4601. [PubMed]
24. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290:G199–G203. [PubMed]
25. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta. 2006;1763:690–699. [PubMed]
26. Verga Falzacappa MV, Muckenthaler MU. Hepcidin: iron-hormone and anti-microbial peptide. Gene. 2005;364:37–44. [PubMed]
27. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810. [PubMed]

Articles from World Journal of Gastroenterology are provided here courtesy of Baishideng Publishing Group Inc